Key Developments: Lonza Group AG (LONN.VX)

LONN.VX on Virt-X Level 1

118.30CHF
22 Sep 2014
Price Change (% chg)

CHF1.90 (+1.63%)
Prev Close
CHF116.40
Open
CHF116.20
Day's High
CHF118.60
Day's Low
CHF115.60
Volume
144,699
Avg. Vol
184,378
52-wk High
CHF118.60
52-wk Low
CHF71.75

Search Stocks

Latest Key Developments (Source: Significant Developments)

Lonza Group AG reiterates FY 2014 outlook
Thursday, 24 Jul 2014 01:00am EDT 

Lonza Group AG:Reiterates full FY 2014 outlook with CORE EBIT growth of about 10 pct and sales growth of about 5 pct.  Full Article

Lonza Group AG confirms FY 2014 outlook
Thursday, 24 Apr 2014 02:37am EDT 

Lonza Group AG:Confirms FY 2014 outlook.Says on track to deliver revenue growth of about 5 pct and CORE EBIT growth of about 10 pct in FY 2014.FY 2013 revenue of 3,584 million Swiss francs.  Full Article

Lonza Group AG proposes cash dividend for 2013
Thursday, 23 Jan 2014 01:03am EST 

Lonza Group AG:Says Board of Directors is proposing a cash dividend of 2.15 Swiss Franc per share for 2013.  Full Article

Lonza Group AG issues FY 2014 guidance and sustains mid FY 2015 outlook
Wednesday, 22 Jan 2014 07:00pm EST 

Lonza Group AG:Expects FY 2014 CORE EBIT growth of about 10 pct.Expects FY 2014 revenue growth of approximately 5 pct.FY 2013 revenue of 3,584 million Swiss francs.FY 2014 revenue of 3,893 million Swiss francs - Thomson Reuters I/B/E/S.Says for FY 2015, mid-term targets are unchanged.  Full Article

Lonza Group AG extends partnership with Pharmacyclics Inc to support manufacturing of recently approved Oncology Therapeutic, IMBRUVICA
Monday, 13 Jan 2014 01:31am EST 

Lonza Group AG:Says it has established an agreement with Pharmacyclics Inc. to support the commercial and clinical production of its first-in-class oral oncology drug, IMBRUVICA.Says this agreement follows a multi-year partnership, including the development and clinical manufacturing, which was utilized for Pharmacyclics’ NDA submission and FDA approval of their lead product for oncology treatment.Says under the long term agreement, Lonza continue to support the production of commercial and clinical material.  Full Article

Lonza Group AG signs exclusive agreement with Index Ventures
Thursday, 9 Jan 2014 01:31am EST 

Lonza Group AG:Says an exclusive agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor.Says over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.Says it is a five year agreement includes all companies where Index Ventures will be the majority shareholder.  Full Article

Chugai Pharma Manufacturing adopts Lonza Group AG's MODA-EM Quality Control Microbiology Automation Platform
Friday, 20 Dec 2013 01:30am EST 

Lonza Group AG:Says Chugai Pharmaceutical Manufacturing Co., Ltd (CPMC) has adopted Lonza’s Quality Control Microbiology automation platform, MODA-EM for their environmental and utility monitoring programs.Says CPMC will utilize the MODA-EM Technology at their Utsunomiya Plant in Japan, for capturing, tracking and trending QC Microbiology information.  Full Article

Lonza Group AG Reaffirms FY 2013 Guidance
Thursday, 31 Oct 2013 02:00am EDT 

Lonza Group AG announced that it reiterates its fiscal year 2013 CORE-EBIT guidance growth of approximately 10%.  Full Article

Lonza Group AG and Sorrento Therapeutics, Inc. Sign Non-exclusive Research License Agreement for Research on Lonza's GS Xceed Gene Expression System
Wednesday, 7 Aug 2013 01:30am EDT 

Lonza Group AG and Sorrento Therapeutics, Inc. announced that they have signed a non-exclusive research license agreement for Sorrento's access to Lonza's GS Xceed Gene Expression System. The GS Xceed System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento's product portfolio. The research license agreement will give Sorrento access to Lonza's GS technology for use in Sorrento's maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease. Sorrento has shown yields of up to 3g/L with the GS Xceed System, in the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2), an important anti-angiogenesis target for a number of solid tumor indications. Several monoclonal antibodies (mAbs) will be produced and developed under the new agreement, including Sorrento's lead anti-PD-L1 and anti-PD-1 antibodies, as well as a selection of traditionally difficult-to-obtain anti-chemokine receptor mAbs.  Full Article

Lonza Group AG and BioWa, Inc. Enter Research Agreements with Pfizer Inc. on POTELLIGENT CHOK1SV Cell Line
Tuesday, 30 Jul 2013 01:30am EDT 

Lonza Group AG announced that together with BioWa, Inc. it has entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT CHOK1SV Cell Line in the research and development of multiple antibodies in Pfizer's pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa's engineered glycosylation POTELLIGENT Technology with Lonza's industry GS Gene Expression System. The GS System includes Lonza's host cell line, CHOK1SV.  Full Article

Lonza courts biotech backers to shore up outsourcing contracts

ZURICH - Swiss drugs industry supplier Lonza Group AG is courting the financial backers of biotech firms to help secure a steady stream of projects and offset some of the volatility of outsourced production contracts, a senior executive said.

Search Stocks